Substance Abuse Treatment Market (By Treatment Type: Tobacco/Nicotine and Vaping, Alcohol, Marijuana, Synthetic Cannabinoids, Prescription and Over-the-counter Medications, Others; By End-use: Hospitals, Clinics, Rehabilitation Centers, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Substance Abuse Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Substance Abuse Treatment Market, by Treatment Type, 2024-2034
8.1.1. Tobacco/Nicotine and Vaping
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Alcohol
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Marijuana
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Synthetic Cannabinoids
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Prescription and Over-the-counter Medications
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2034)
9.1. Substance Abuse Treatment Market, by End-use, 2024-2034
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Clinics
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Rehabilitation Centers
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.1.2. Market Revenue and Forecast, by End-use (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by End-use (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.2.2. Market Revenue and Forecast, by End-use (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by End-use (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by End-use (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by End-use (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by End-use (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by End-use (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by End-use (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.4.2. Market Revenue and Forecast, by End-use (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by End-use (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by End-use (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by End-use (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.5.2. Market Revenue and Forecast, by End-use (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by End-use (2021-2034)
11.1. American Addiction Centers, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Promises Behavioral Health
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Hazelden Betty Ford Foundation
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. CRC Health Group
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Behavioral Health Group (BHG)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. The Recovery Village
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. BayMark Health Services
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Landmark Recovery
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. AAC Holdings, Inc. (AAC)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Phoenix House
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample